This report originally published at defense.gov.
WASHINGTON, Jan. 16, 2018 — The Defense Department and Food and Drug Administration launched a joint pilot program to prioritize efficiently developing safe and effective medical products to save the lives of U.S. warfighters, officials of the agencies announced this morning in a media teleconference.
“The partnership we announced today reflects the invaluable collaboration between our organizations,” Tom McCaffery, acting assistant secretary of defense for health affairs said.
“It strengthens our ability to equip our troops with the best possible medical support, and it helps us achieve our mission of providing battlefield care to support our entire military’s effort to achieve a safer, more secure world,” he added.
The FDA is fully committed to working closely with DoD to expedite availability of medical products that are critical to the health of service members, particularly those used to treat injuries in battlefield settings, said FDA Commissioner Dr. Scott Gottlieb, a physician and medical policy expert.
“Ensuring our nation’s warfighters have safe and effective medical products is a top priority for the agency,” he said. “By standing up a collaborative program with DoD, we hope to address DoD’s immediate product priorities and ensure these products are developed and made available in the most expeditious manner possible.”
Quick Access Is Critical
Fast access to lifesaving medical products on the battlefield is part and parcel of DoD’s efforts to support forces operating around the world, McCaffery said.
“[It’s also] essential to upholding our responsibility to the men and women of our military who risk their lives for us,” he added.
FDA’s expertise and guidance will help DoD put the best, most-effective products in the hands of battlefield medical personnel, he emphasized. “We look forward to working with our FDA partners on this important pilot program to ensure delivery of critical battlefield medicine to our deployed troops around the world.”
The framework for the program was put in place through House Res. 4374, which authorized DoD to request, and the FDA to provide, assistance to expedite development, in addition to the FDA’s review of products to diagnose, treat or prevent serious or life-threatening diseases or conditions facing American military personnel, according to an FDA press release.
Working Closely on Needs
Using the law’s expanded authorities, FDA will work closely with DoD’s Health Affairs to better understand the military’s medical needs for deployed personnel, give the highest level of attention to and expedite its review of priority DoD medical products, provide ongoing technical advice to Health Affairs to rapidly develop and manufacture medical products for use by the military, and take a closer look at products under development for opportunities to push their availability, the release said.
While the availability of biological items such as blood products takes priority, the FDA and DoD are aware of the need for a broad range of medical products for service members — such as preventive vaccines and therapeutics — and these needs will continue to evolve in the future, the FDA release said.
(Follow Terri Moon Cronk on Twitter: @MoonCronkDOD)
U.S. Department of Defense (DOD) reports are created independently of American Military News (AMN) and are distributed by AMN in accordance with applicable guidelines and copyright guidance. Use of DOD reports do not imply endorsement of AMN. AMN is a privately owned media company and has no affiliation with the DOD.